Better Therapeutics, Inc. (NASDAQ:BTTX) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET

Company Participants

Kevin Appelbaum – Co-Founder and Chief Executive Officer

Mark Berman – Chief Medical Officer

Mark Heinen – Chief Financial Officer

Conference Call Participants

Thomas Flaten – Lake Street Capital

Charles Rhyee – Cowen

Keay Nakae – Chardan

Rahul Rakhit – LifeSci Capital

Operator

Good morning, and welcome to the Better Therapeutics First Quarter 2022 Financial Results and Business Update Conference Call. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions]

I would now like to hand the call over to Kevin Appelbaum, Co-Founder and Chief Executive Officer. Please begin.

Kevin Appelbaum

Thank you, operator. Good morning, everyone. And welcome to the Better Therapeutics conference call to discuss our first quarter 2022 financial results and business update. Our press release was issued this morning and can be found in the Investors section of our corporate website at bettertx.com.

Joining me on the call this morning are Dr. Mark Berman, our Chief Medical Officer; and Mark Heinen, our Chief Financial Officer. During today's call, the team will provide a business and financial overview of the first quarter of 2022 and provide our outlook for the second quarter of 2022 and beyond. A Q&A session will follow our prepared remarks.

Before we begin and as a reminder, today's discussion will include forward-looking statements related to Better Therapeutics current plans and expectations, which are subject to certain risks and uncertainties. Actual results may differ materially due to various important factors, including those described in the risk factors section of our most recent SEC filing. These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation to publicly update these statements.

Better Therapeutics is successfully executing on our strategic priorities in 2022. Most notably, we have made significant progress in validating and advancing the clinical development of our first-in-class prescription digital therapeutic for the treatment of Type 2 diabetes. I will share more in our progress momentarily, but I want to begin with the headline that with continued positive data, we expect to file a de novo classification request with the FDA in the third quarter of 2022, seeking marketing authorization of BT-001 for the treatment of patients with Type 2 diabetes.